Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/5412
Title: Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Authors: Santos, D. L. 
Moreno, A. J. M. 
Leino, R. L. 
Froberg, M. K. 
Wallace, K. B. 
Keywords: Adriamycin; Adrenergic; Toxicity
Issue Date: 2002
Citation: Toxicology and Applied Pharmacology. 185:3 (2002) 218-227
Abstract: Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin. Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the pathogenic process. The objective of this investigation was to test the hypothesis that carvedilol, a nonselective [beta]-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity. Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), carvedilol (1 mg/kg ip/week), or the combination of the two drugs. Heart mitochondria isolated from doxorubicin-treated rats exhibited depressed rates for state 3 respiration (336 ± 26 versus 425 ± 53 natom O/min/mg protein) and a lower respiratory control ratio (RCR) (4.3 ± 0.6 versus 5.8 ± 0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats. Doxorubicin treatment also caused a decrease in RCR for liver mitochondria (3.9 ± 0.9 versus 5.6 ± 0.7 for control rats) and inhibition of hepatic cytochrome oxidase activity. Coadministration of carvedilol decreased the extent of cellular vacuolization in cardiac myocytes and prevented the inhibitory effect of doxorubicin on mitochondrial respiration in both heart and liver. Carvedilol also prevented the decrease in mitochondrial Ca2+ loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.
URI: http://hdl.handle.net/10316/5412
Rights: openAccess
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat 
file66ee3649624b45b0b7ab88ee2d359fe1.pdf520.79 kBAdobe PDFView/Open
Show full item record

Page view(s) 50

411
checked on Jun 18, 2019

Download(s)

87
checked on Jun 18, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.